New Mexico Educational Retirement Board Has $5.84 Million Stake in Bristol Myers Squibb Company $BMY

New Mexico Educational Retirement Board increased its position in shares of Bristol Myers Squibb Company (NYSE:BMY) by 8.9% during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 101,334 shares of the biopharmaceutical company’s stock after acquiring an additional 8,300 shares during the period. New Mexico Educational Retirement Board’s holdings in Bristol Myers Squibb were worth $5,839,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. Darwin Wealth Management LLC acquired a new position in shares of Bristol Myers Squibb during the second quarter worth $25,000. Swiss RE Ltd. acquired a new position in Bristol Myers Squibb during the 4th quarter worth about $25,000. Davis Asset Management L.P. bought a new stake in shares of Bristol Myers Squibb in the 2nd quarter valued at about $27,000. Bayban bought a new stake in shares of Bristol Myers Squibb in the 4th quarter valued at about $31,000. Finally, EQ Wealth Advisors LLC acquired a new stake in shares of Bristol Myers Squibb in the fourth quarter valued at about $32,000. 76.41% of the stock is currently owned by institutional investors.

Key Headlines Impacting Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: The FDA approved Zenbexus (iberdomide), an oral therapy for adults with relapsed or refractory multiple myeloma when used with Johnson & Johnson’s Darzalex and dexamethasone. As the first approved CELMoD therapy in this setting, Zenbexus provides BMY with another potential oncology growth driver and may help diversify its product portfolio. Will ZENBEXUS’s First-in-Class CELMoD Approval Based on MRD-Negative CR Change Bristol Myers Squibb’s Narrative?
• Positive Sentiment: BMY paid Atrium Therapeutics a $15 million milestone after Atrium delivered a lead RNA compound for an undisclosed cardiovascular indication. The payment signals progress in the collaboration and could strengthen investor confidence in BMY’s cardiovascular research pipeline, although the program remains early-stage and details are limited. Can Atrium Therapeutics’ $15 Million Milestone From Bristol-Myers Squibb Validate its RNA Platform?
• Neutral Sentiment: BMY announced a follow-on study for its deucravacitinib program, indicating continued investment in autoimmune diseases. The update supports the company’s longer-term pipeline strategy but does not yet provide a near-term revenue catalyst. Bristol-Myers Squibb Extends Deucravacitinib Program
• Negative Sentiment: Cytokinetics reported a first-ever Phase 3 success in non-obstructive hypertrophic cardiomyopathy, intensifying competition with BMY’s Camzyos cardiovascular franchise. A successful rival could pressure Camzyos’ longer-term growth prospects. Cytokinetics Scores a First-Ever in Its Rivalry Against Bristol Myers
• Negative Sentiment: BMY ended its partnership with Cellares after determining that the company’s manufacturing platform could not produce Breyanzi at commercial scale. The decision may delay planned capacity expansion for the cell therapy and raises questions about Breyanzi’s ability to meet future demand. Bristol-Myers Squibb’s Cellares Exit Raises Questions Over Breyanzi Growth
• Negative Sentiment: SVP Phil Holzer sold 500 BMY shares for approximately $33,750. The relatively small transaction is unlikely to materially affect fundamentals, but it adds a modest negative signal. Bristol Myers Squibb SVP Phil Holzer Sells 500 Shares

Wall Street Analysts Forecast Growth

Several analysts recently commented on the company. Raymond James Financial began coverage on Bristol Myers Squibb in a report on Wednesday, August 5th. They issued a “strong-buy” rating on the stock. Truist Financial restated a “buy” rating and issued a $70.00 price target (up from $65.00) on shares of Bristol Myers Squibb in a research report on Friday, July 31st. Wells Fargo & Company set a $65.00 price objective on shares of Bristol Myers Squibb and gave the company an “equal weight” rating in a research note on Friday, July 31st. UBS Group cut shares of Bristol Myers Squibb from a “buy” rating to a “neutral” rating in a research report on Wednesday, August 5th. Finally, BMO Capital Markets reissued a “market perform” rating on shares of Bristol Myers Squibb in a research note on Monday, July 27th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, ten have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Bristol Myers Squibb presently has an average rating of “Moderate Buy” and a consensus price target of $66.06.

Bristol Myers Squibb Trading Down 0.5%

Shares of BMY stock opened at $66.62 on Friday. The company has a market cap of $136.09 billion, a P/E ratio of 14.67, a PEG ratio of 0.17 and a beta of 0.22. Bristol Myers Squibb Company has a fifty-two week low of $42.52 and a fifty-two week high of $68.64. The stock has a 50 day simple moving average of $61.76 and a two-hundred day simple moving average of $59.68. The company has a debt-to-equity ratio of 1.89, a quick ratio of 1.38 and a current ratio of 1.53.

Bristol Myers Squibb (NYSE:BMY) last announced its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $2.04 EPS for the quarter, topping the consensus estimate of $1.60 by $0.44. Bristol Myers Squibb had a net margin of 18.87% and a return on equity of 66.90%. The company had revenue of $12.97 billion during the quarter, compared to the consensus estimate of $11.74 billion. During the same quarter last year, the firm posted $1.46 EPS. The company’s quarterly revenue was up 5.7% on a year-over-year basis. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. Research analysts forecast that Bristol Myers Squibb Company will post 6.95 earnings per share for the current year.

Bristol Myers Squibb Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Monday, August 3rd. Shareholders of record on Thursday, July 2nd were paid a $0.63 dividend. This represents a $2.52 annualized dividend and a yield of 3.8%. The ex-dividend date of this dividend was Thursday, July 2nd. Bristol Myers Squibb’s payout ratio is 55.51%.

Insider Buying and Selling at Bristol Myers Squibb

In other news, SVP Phil M. Holzer sold 500 shares of the stock in a transaction dated Tuesday, August 25th. The shares were sold at an average price of $67.50, for a total transaction of $33,750.00. Following the transaction, the senior vice president owned 16,862 shares of the company’s stock, valued at $1,138,185. This represents a 2.88% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 0.05% of the company’s stock.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.